These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

498 related items for PubMed ID: 33054456

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Futibatinib: A Review in Locally Advanced and Metastatic Cholangiocarcinoma.
    Hoy SM.
    Target Oncol; 2024 May; 19(3):473-480. PubMed ID: 38724820
    [Abstract] [Full Text] [Related]

  • 5. Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors.
    Sootome H, Fujita H, Ito K, Ochiiwa H, Fujioka Y, Ito K, Miura A, Sagara T, Ito S, Ohsawa H, Otsuki S, Funabashi K, Yashiro M, Matsuo K, Yonekura K, Hirai H.
    Cancer Res; 2020 Nov 15; 80(22):4986-4997. PubMed ID: 32973082
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. FDA Approval Summary: Futibatinib for Unresectable Advanced or Metastatic, Chemotherapy Refractory Intrahepatic Cholangiocarcinoma with FGFR2 Fusions or Other Rearrangements.
    Gandhy SU, Casak SJ, Mushti SL, Cheng J, Subramaniam S, Zhao H, Zhao M, Bi Y, Liu G, Fan J, Adeniyi O, Charlab R, Kufrin D, Thompson MD, Jarrell K, Auth D, Lemery SJ, Pazdur R, Kluetz PG, Fashoyin-Aje LA.
    Clin Cancer Res; 2023 Oct 13; 29(20):4027-4031. PubMed ID: 37289037
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Pemigatinib, a potent inhibitor of FGFRs for the treatment of cholangiocarcinoma.
    Merz V, Zecchetto C, Melisi D.
    Future Oncol; 2021 Feb 13; 17(4):389-402. PubMed ID: 33034201
    [Abstract] [Full Text] [Related]

  • 16. Antitumor effect of FGFR inhibitors on a novel cholangiocarcinoma patient derived xenograft mouse model endogenously expressing an FGFR2-CCDC6 fusion protein.
    Wang Y, Ding X, Wang S, Moser CD, Shaleh HM, Mohamed EA, Chaiteerakij R, Allotey LK, Chen G, Miyabe K, McNulty MS, Ndzengue A, Barr Fritcher EG, Knudson RA, Greipp PT, Clark KJ, Torbenson MS, Kipp BR, Zhou J, Barrett MT, Gustafson MP, Alberts SR, Borad MJ, Roberts LR.
    Cancer Lett; 2016 Sep 28; 380(1):163-73. PubMed ID: 27216979
    [Abstract] [Full Text] [Related]

  • 17. Intrahepatic Cholangiocarcinoma: State of the Art of FGFR Inhibitors.
    Wu T, Jiang X, Zhang X, Wu B, Xu B, Liu X, Zheng L, Wang Y.
    Cancer Control; 2021 Sep 28; 28():1073274821989314. PubMed ID: 33618536
    [Abstract] [Full Text] [Related]

  • 18. Clinical complexity of utilizing FGFR inhibitors in cancer therapeutics.
    Chandana SR, Babiker HM, Mahadevan D.
    Expert Opin Investig Drugs; 2020 Dec 28; 29(12):1413-1429. PubMed ID: 33074030
    [Abstract] [Full Text] [Related]

  • 19. Futibatinib: A Potent and Irreversible Inhibitor of Fibroblast Growth Factor Receptors for Treatment of the Bile Duct Cancer.
    De SK.
    Curr Med Chem; 2024 Dec 28; 31(6):666-670. PubMed ID: 37062061
    [Abstract] [Full Text] [Related]

  • 20. FGFR Inhibitors: Clinical Activity and Development in the Treatment of Cholangiocarcinoma.
    King G, Javle M.
    Curr Oncol Rep; 2021 Jul 16; 23(9):108. PubMed ID: 34269915
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.